PAS — Pascal Biosciences Income Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
Annual income statement for Pascal Biosciences, fiscal year end - November 30th, CAD millions except per share, conversion factor applied.
2018 November 30th | 2019 November 30th | 2020 November 30th | 2021 November 30th | 2022 November 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 3.34 | 3.43 | 1.24 | 1.09 | 0.359 |
| Operating Profit | -3.34 | -3.43 | -1.24 | -1.09 | -0.359 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -3.24 | -3.41 | -1.24 | -1.09 | -0.48 |
| Net Income After Taxes | -3.24 | -3.41 | -1.24 | -1.09 | -0.48 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -3.24 | -3.41 | -1.24 | -1.09 | -0.48 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -3.24 | -3.41 | -1.24 | -1.09 | -0.48 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.053 | -0.065 | -0.023 | -0.017 | -0.009 |